Raymond James initiated coverage on AbbVie Inc (NYSE: ABBV) as the company looks beyond Humira's loss of exclusivity and has several levers to set up long-term growth.
AbbVie Inc (NASDAQ: ABBV) released data from its Phase 3 CANOVA study evaluating venetoclax (Venclexta/ Venclyxto) plus dexamethasone (VenDex) for patients with t(11;14)-positive relapsed or refractory (R/R) multiple myeloma who have received
Walgreens Boots Alliance Inc. (NASDAQ: WBA) is reportedly considering appointing Tim Wentworth, a former executive at Cigna Group (NYSE: CI), as its next CEO amid a search for leadership